Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01200342 | Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00588341 | Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection | completed | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2016 | clinicaltrials |
| NCT01565837 | Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma(SART) | unknown | Phase 2 | 50 | Wolfram SamlowskiOTHER | 1 | Feb 1, 2016 | clinicaltrials |
| NCT02452281 | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Rabih SaidOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT02662725 | Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases(IPI+RTS) | completed | Phase 2 | 73 | University Hospital, LilleOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01435369 | Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma | completed | Phase 2 | 103 | Medivation, Inc.INDUSTRY | 2 | Jan 21, 2016 | clinicaltrials |
| NCT01983124 | Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib(BeyPro1) | completed | Phase 2 | 31 | Paola QueiroloOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00673361 | Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma | terminated | Phase 2 | 9 | Duke UniversityOTHER | 0 | Jan 13, 2016 | clinicaltrials |
| NCT00462982 | Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma | completed | Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00568451 | Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT01028222 | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation(TEAM) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 30, 2015 | clinicaltrials |
| NCT00289016 | A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma | completed | Phase 2 | 50 | BioVex LimitedINDUSTRY | 2 | Dec 18, 2015 | clinicaltrials |
| NCT02574260 | An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) | completed | Phase 2 | 3 | BioVex LimitedINDUSTRY | 0 | Dec 17, 2015 | clinicaltrials |
| NCT00185302 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma | completed | Phase 2 | 28 | BayerINDUSTRY | 0 | Dec 14, 2015 | clinicaltrials |
| NCT00003715 | Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma | terminated | Phase 2 | 425 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00257465 | Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma | completed | Phase 1 / Phase 2 | 82 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01709162 | Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma | terminated | Phase 2 | 31 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 30, 2015 | clinicaltrials |
| NCT01236573 | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | terminated | Phase 1 / Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01474551 | Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT00096382 | Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00610311 | Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00612222 | Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00704938 | Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer | terminated | Phase 2 | 3 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00706992 | Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00923195 | Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01160445 | Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01273181 | MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00665470 | Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2015 | clinicaltrials |
| NCT01495572 | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 15, 2015 | clinicaltrials |
| NCT00612664 | Phase II, 2nd Line Melanoma - RAND Monotherapy | completed | Phase 2 | 158 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 12, 2015 | clinicaltrials |
| NCT01882946 | Safety and Efficacy Study of DCVax-Direct in Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Northwest BiotherapeuticsINDUSTRY | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01376713 | Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma | completed | Phase 2 | 10 | Medical University of ViennaOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00002973 | Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma | completed | Phase 2 | 34 | University of Wisconsin, MadisonOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00085306 | Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma | completed | Phase 2 | 21 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00403377 | Investigation of a Behavioral Substitute for Sunbathing | completed | Phase 1 / Phase 2 | 307 | University of Massachusetts, WorcesterOTHER | 1 | Oct 1, 2015 | clinicaltrials |
| NCT00432107 | A Study to Assess APO866 for the Treatment of Advanced Melanoma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Sep 29, 2015 | clinicaltrials |
| NCT01764009 | Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma(AIMM) | withdrawn | Phase 1 / Phase 2 | 0 | Valerio TherapeuticsINDUSTRY | 2 | Sep 11, 2015 | clinicaltrials |
| NCT00818480 | An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 | completed | Phase 2 | 10 | Astellas Pharma IncINDUSTRY | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01009775 | A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma | completed | Phase 2 | 64 | Astellas Pharma IncINDUSTRY | 2 | Sep 4, 2015 | clinicaltrials |
| NCT01729663 | Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients | unknown | Phase 2 / Phase 3 | 108 | Laboratorio Pablo Cassara S.R.L.INDUSTRY | 1 | Sep 2, 2015 | clinicaltrials |
| NCT00139360 | Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma | completed | Phase 2 | 35 | Haukeland University HospitalOTHER | 1 | Aug 27, 2015 | clinicaltrials |
| NCT00937625 | T-cell Based Immunotherapy for of Melanoma | completed | Phase 1 / Phase 2 | 31 | Inge Marie SvaneOTHER | 1 | Aug 18, 2015 | clinicaltrials |
| NCT00866177 | MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 167 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2015 | clinicaltrials |
| NCT01480323 | A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 | completed | Phase 2 | 15 | University Hospital TuebingenOTHER | 1 | Jul 21, 2015 | clinicaltrials |
| NCT02498756 | Cytokine-induced Killer Study for Patients With Stage II Melanoma | not yet recruiting | Phase 2 | 300 | The First People's Hospital of ChangzhouOTHER | 0 | Jul 15, 2015 | clinicaltrials |
| NCT00855452 | Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors(rIL-2(LAK)) | completed | Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT01681212 | Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma | completed | Phase 2 | 21 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00022464 | CCI-779 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | — | City of Hope Medical CenterOTHER | 2 | Jun 8, 2015 | clinicaltrials |
| NCT00110994 | Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma | completed | Phase 2 | 101 | BayerINDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Feb 11, 2016source: clinicaltrials